The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA
Abstract
The hypothesis that the antitumor prodrug temozolomide is ring-opened to MTIC which then further breaks down to a reactive diazonium ion at guanine-rich sequences in DNA has been probed by NMR spectroscopy and computational techniques. Temozolomide is stable at acid pH but decomposes to MTIC at pH > 7; in contrast, MTIC is stable at alkaline pH values but rapidly fragments in a methylating mode at pH < 7. The proximate methylating agent is the reactive methyldiazonium species. Runs of guanine residues represent an accessible nucleophilic microenvironment in DNA site-specific conversion of the prodrug temozolomide to MTIC possibly via an activated water molecule in the major groove. Molecular modeling of the structure of temozolomide indicates that the prodrug can make a favorable noncovalent encounter with DNA. The known structure-activity relationships as well as the biological and clinical properties of temozolomide can be interpreted in terms of this model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new force field for molecular mechanical simulation of nucleic acids and proteins
Weiner, S. J., Kollman, P. A., Case, D. A., Singh, U. C., Ghio, C., Alagona, G., Profeta, S., & Weiner, P. (1984) · Journal of the American Chemical Society · doi:10.1021/ja00315a051 · Cited by 4,639
(1989) · PubMed · Cited by 3,343
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E., Blackledge, G., Slack, J., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488
Self-citationMolecular electrostatic potential of the nucleic acids
Pullman, A., & Pullman, B. (1981) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500002341 · Cited by 411
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387
Self-citationO'Reilly, S. M., Newlands, E. S., Brampton, M., Glaser, M. G., Rice-Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., Lewis, P., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80198-4 · Cited by 277
Self-citationRichardson, K. K., Richardson, F. C., Crosby, R. M., Swenberg, J. A., & Skopek, T. R. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.2.344 · Cited by 226
O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.
Citron, M. L., Decker, R., Chen, S., Schneider, S., Graver, M. L., Kleynerman, L., Kahn, L. B., White, A., Schoenhaus, M., & Yarosh, D. B. (1991) · PubMed · Cited by 112
New Avenues in Developmental Cancer Chemotherapy
Harrap, K. R., & Connors, T. A. (1987) · Medical Entomology and Zoology · Cited by 95
Tsang, L. L. H., Quarterman, C. P., Gescher, A., & Slack, J. A. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00688855 · Cited by 92
Self-citation
Cited by
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
Self-citationTherapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
The role of PARP in DNA repair and its therapeutic exploitation
Javle, M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Triazene compounds: Mechanism of action and related DNA repair systems
MARCHESI, F., TURRIZIANI, M., TORTORELLI, G., AVVISATI, G., TORINO, F., & DEVECCHIS, L. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.08.003 · Cited by 299
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target
Fishel, M. L., & Kelley, M. R. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.04.005 · Cited by 278
Current and future developments in the use of temozolomide for the treatment of brain tumours
Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00489-2 · Cited by 254
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
Huang, Y., Sun, G., Sun, X., Li, F., Zhao, L., Zhong, R., & Peng, Y. (2020) · Cancers · doi:10.3390/cancers12113332 · Cited by 124
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas
Agnihotri, S., Wolf, A., Munoz, D. M., Smith, C. J., Gajadhar, A., Restrepo, A., Clarke, I. D., Fuller, G. N., Kesari, S., Dirks, P. B., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102099 · Cited by 92
Metadata
- Authors
- Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1994-08-01
- Volume
- 33
- Issue
- 31
- Pages
- 9045-9051
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2079203845
- Cited by
- 442
- References
- 13
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.